Tekla Life Sciences Investors (HQL) - Net Assets
Based on the latest financial reports, Tekla Life Sciences Investors (HQL) has net assets worth $513.66 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($515.38 Million) and total liabilities ($1.73 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check tangible equity quality of Tekla Life Sciences Investors to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $513.66 Million |
| % of Total Assets | 99.67% |
| Annual Growth Rate | 5.05% |
| 5-Year Change | -1.87% |
| 10-Year Change | 23.78% |
| Growth Volatility | 28.46 |
Tekla Life Sciences Investors - Net Assets Trend (1996–2025)
This chart illustrates how Tekla Life Sciences Investors's net assets have evolved over time, based on quarterly financial data. See HQL cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Tekla Life Sciences Investors (1996–2025)
The table below shows the annual net assets of Tekla Life Sciences Investors from 1996 to 2025. For live valuation and market cap data, see Tekla Life Sciences Investors stock valuation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-09-30 | $513.66 Million | +11.74% |
| 2024-09-30 | $459.69 Million | +14.37% |
| 2023-09-30 | $401.93 Million | +1.01% |
| 2022-09-30 | $397.90 Million | -23.98% |
| 2021-09-30 | $523.44 Million | +8.24% |
| 2020-09-30 | $483.57 Million | +25.88% |
| 2019-09-30 | $384.16 Million | -19.21% |
| 2018-09-30 | $475.49 Million | +1.96% |
| 2017-09-30 | $466.35 Million | +12.38% |
| 2016-09-30 | $414.97 Million | -10.34% |
| 2015-09-30 | $462.84 Million | +4.22% |
| 2014-09-30 | $444.09 Million | +46.91% |
| 2013-09-30 | $302.29 Million | +33.12% |
| 2012-09-30 | $227.08 Million | +33.11% |
| 2011-09-30 | $170.60 Million | -32.14% |
| 2010-09-30 | $251.40 Million | +1.13% |
| 2009-09-30 | $248.60 Million | -10.51% |
| 2008-09-30 | $277.80 Million | -9.81% |
| 2007-09-30 | $308.00 Million | +14.88% |
| 2006-09-30 | $268.10 Million | +16.92% |
| 2005-09-30 | $229.30 Million | +19.55% |
| 2004-09-30 | $191.80 Million | +0.74% |
| 2003-09-30 | $190.40 Million | +20.81% |
| 2002-09-30 | $157.60 Million | -26.73% |
| 2001-09-30 | $215.10 Million | +115.10% |
| 1998-09-30 | $100.00 Million | -24.24% |
| 1997-09-30 | $132.00 Million | +7.23% |
| 1996-09-30 | $123.10 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Tekla Life Sciences Investors's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 7760423200.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (September 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $77.60 Million | 15.11% |
| Common Stock | $295.99K | 0.06% |
| Other Components | $435.76 Million | 84.83% |
| Total Equity | $513.66 Million | 100.00% |
Tekla Life Sciences Investors Competitors by Market Cap
The table below lists competitors of Tekla Life Sciences Investors ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Levinstein Eng
TA:LEVI
|
$546.19 Million |
|
Henan Huaying Agricultural Development Co Ltd
SHE:002321
|
$546.19 Million |
|
Cheng Du Sheng Nuo Biotec Co. Ltd. A
SHG:688117
|
$546.28 Million |
|
Jiangsu Fasten Co Ltd
SHE:000890
|
$546.34 Million |
|
Yantai Ishikawa Sealing Technology Co.Ltd.
SHE:301020
|
$546.07 Million |
|
Bridgewater Bancshares Inc
NASDAQ:BWB
|
$545.96 Million |
|
Beijing Tieke Shougang Railway Tech Co Ltd
SHG:688569
|
$545.95 Million |
|
GFT Technologies SE
XETRA:GFT
|
$545.81 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Tekla Life Sciences Investors's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 459,694,606 to 513,655,946, a change of 53,961,340 (11.7%).
- Net income of 85,594,346 contributed positively to equity growth.
- Dividend payments of 31,633,006 reduced retained earnings.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $85.59 Million | +16.66% |
| Dividends Paid | $31.63 Million | -6.16% |
| Total Change | $- | 11.74% |
Book Value vs Market Value Analysis
This analysis compares Tekla Life Sciences Investors's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.01x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 0.00x to 1.01x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1996-09-30 | $18428.14 | $17.96 | x |
| 1997-09-30 | $18830.24 | $17.96 | x |
| 1998-09-30 | $13717.42 | $17.96 | x |
| 2001-09-30 | $23090.13 | $17.96 | x |
| 2002-09-30 | $15139.29 | $17.96 | x |
| 2003-09-30 | $16687.12 | $17.96 | x |
| 2004-09-30 | $15890.64 | $17.96 | x |
| 2005-09-30 | $18183.98 | $17.96 | x |
| 2006-09-30 | $13941.76 | $17.96 | x |
| 2007-09-30 | $15338.65 | $17.96 | x |
| 2008-09-30 | $13178.37 | $17.96 | x |
| 2009-09-30 | $11325.74 | $17.96 | x |
| 2010-09-30 | $11510.99 | $17.96 | x |
| 2011-09-30 | $11700.96 | $17.96 | x |
| 2012-09-30 | $15738.16 | $17.96 | x |
| 2013-09-30 | $20160.66 | $17.96 | x |
| 2014-09-30 | $23366.85 | $17.96 | x |
| 2015-09-30 | $23511.12 | $17.96 | x |
| 2016-09-30 | $20.01 | $17.96 | x |
| 2017-09-30 | $21.84 | $17.96 | x |
| 2018-09-30 | $21.22 | $17.96 | x |
| 2019-09-30 | $16.55 | $17.96 | x |
| 2020-09-30 | $20.28 | $17.96 | x |
| 2021-09-30 | $21.58 | $17.96 | x |
| 2022-09-30 | $15.49 | $17.96 | x |
| 2023-09-30 | $14.21 | $17.96 | x |
| 2024-09-30 | $16.38 | $17.96 | x |
| 2025-09-30 | $17.79 | $17.96 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Tekla Life Sciences Investors utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 16.66%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 99.08%
- • Asset Turnover: 0.17x
- • Equity Multiplier: 1.00x
- Recent ROE (16.66%) is above the historical average (5.59%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1996 | 17.72% | 5192.86% | 0.00x | 1.00x | $9.50 Million |
| 1997 | 11.51% | 4746.88% | 0.00x | 1.00x | $1.99 Million |
| 1998 | -30.38% | -21700.00% | 0.00x | 1.01x | $-40.38 Million |
| 2001 | -44.16% | -5368.93% | 0.01x | 1.00x | $-116.55 Million |
| 2002 | -31.99% | -5362.77% | 0.01x | 1.00x | $-66.17 Million |
| 2003 | 20.28% | 6331.15% | 0.00x | 1.01x | $19.58 Million |
| 2004 | 3.73% | 2237.50% | 0.00x | 1.01x | $-12.02 Million |
| 2005 | 19.52% | 5029.21% | 0.00x | 1.00x | $21.83 Million |
| 2006 | -8.00% | -932.17% | 0.01x | 1.01x | $-48.25 Million |
| 2007 | 16.40% | 1753.82% | 0.01x | 1.00x | $19.71 Million |
| 2008 | 21.69% | 3607.78% | 0.01x | 1.01x | $32.47 Million |
| 2009 | -8.72% | -4710.87% | 0.00x | 1.07x | $-46.53 Million |
| 2010 | 4.05% | 559.89% | 0.01x | 1.02x | $-14.95 Million |
| 2011 | 21.96% | 6573.68% | 0.00x | 1.01x | $20.41 Million |
| 2012 | 34.19% | 3619.95% | 0.01x | 1.00x | $54.92 Million |
| 2013 | 28.00% | 16380.07% | 0.00x | 1.00x | $54.42 Million |
| 2014 | 20.10% | 10181.17% | 0.00x | 1.00x | $44.86 Million |
| 2015 | 8.75% | 3062.09% | 0.00x | 1.01x | $-5.78 Million |
| 2016 | -2.87% | -189.30% | 0.02x | 1.01x | $-53.41 Million |
| 2017 | 14.70% | 98.20% | 0.15x | 1.00x | $21.92 Million |
| 2018 | 6.03% | 1443.44% | 0.00x | 1.01x | $-18.88 Million |
| 2019 | -18.37% | 0.00% | -0.18x | 1.01x | $-108.84 Million |
| 2020 | 25.45% | 99.17% | 0.26x | 1.00x | $74.70 Million |
| 2021 | 12.33% | 98.24% | 0.12x | 1.02x | $12.19 Million |
| 2022 | -26.29% | 0.00% | -0.25x | 1.04x | $-144.39 Million |
| 2023 | 5.56% | 95.02% | 0.06x | 1.00x | $-17.84 Million |
| 2024 | 18.56% | 98.40% | 0.19x | 1.00x | $39.33 Million |
| 2025 | 16.66% | 99.08% | 0.17x | 1.00x | $34.23 Million |
Industry Comparison
This section compares Tekla Life Sciences Investors's net assets metrics with peer companies in the Asset Management industry.
Industry Context
- Industry: Asset Management
- Average net assets among peers: $1,436,657,108
- Average return on equity (ROE) among peers: -13.34%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Tekla Life Sciences Investors (HQL) | $513.66 Million | 17.72% | 0.00x | $546.13 Million |
| Acadian Asset Management Inc (AAMI) | $49.50 Million | 132.93% | 11.35x | $1.86 Billion |
| AllianceBernstein Holding L.P. (AB) | $1.58 Billion | 11.79% | 0.00x | $3.27 Billion |
| Associated Capital Group Inc (AC) | $898.30 Million | 4.93% | 0.04x | $78.56 Million |
| Abrdn Emerging Markets Equity Income Fund Inc (AEF) | $77.47 Million | -13.30% | 0.03x | $265.69 Million |
| AgriFORCE Growing Systems Ltd (AGRI) | $1.40 Million | -229.54% | 1.40x | $194.14 Million |
| Alpha Compute Corp (ALP) | $4.53 Million | -55.38% | 0.03x | $5.62 Million |
| Alvarium Tiedemann Holdings Inc. (ALTI) | $83.45 Million | -7.38% | 0.39x | $296.12 Million |
| Affiliated Managers Group Inc (AMG) | $337.80 Million | 7.58% | 0.79x | $9.37 Billion |
| Ameriprise Financial Inc (AMP) | $11.31 Billion | 9.70% | 10.60x | $40.38 Billion |
| AMTD IDEA Group (AMTD) | $28.27 Million | 5.22% | 12.77x | $40.58 Million |
About Tekla Life Sciences Investors
Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, … Read more